カテゴリー： 世界, 医療/バイオ, Allied Market Research

多発性骨髄腫の世界市場2021-2031：機会分析・産業予測

【英語タイトル】Multiple Myeloma Market By Drug Type (Chemotherapy, Protease Inhibitors, Monoclonal Antibody, Others), By Disease Type (Active Multiple Myeloma, Smoldering Multiple Myeloma), By End User (Hospitals, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Allied Market Researchが出版した調査資料（ALD23JUN070）・商品コード：ALD23JUN070
・発行会社（調査会社）：Allied Market Research
・発行日：2023年3月
・ページ数：411
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

アライドマーケットリサーチ社の市場調査レポートでは、世界の多発性骨髄腫市場規模が、2021年の19,666.74百万ドルから2031年には53,521.76百万ドルまで拡大し、2022年から2031年までの予測期間中、年平均成長率は10.5％を記録すると推測されています。当レポートでは、多発性骨髄腫の世界市場について多面的に調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、薬物種類別（化学療法、プロテアーゼ阻害剤、モノクローナル抗体、その他）分析、疾患種類別（活性多発性骨髄腫、くすぶり型多発性骨髄腫）分析、エンドユーザー別（病院、診療所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などの内容を整理しています。なお、記載されている企業情報には、Bristol-Myers Squibb Company、Amgen Inc.、Abbvie Inc、Johnson and Johnson、Baxter International Inc.、Takeda Pharmaceutical Company Ltd、Teva Pharmaceutical Industries、Pfizer Inc.、Sanofi、Novartis AGなどが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の多発性骨髄腫市場規模：薬物種類別
- 化学療法の市場規模
- プロテアーゼ阻害剤の市場規模
- モノクローナル抗体の市場規模
- その他薬物の市場規模
・世界の多発性骨髄腫市場規模：疾患種類別
- 活性多発性骨髄腫における市場規模
- くすぶり型多発性骨髄腫における市場規模
・世界の多発性骨髄腫市場規模：エンドユーザー別
- 病院における市場規模
- 診療所における市場規模
- その他エンドユーザーにおける市場規模
・世界の多発性骨髄腫市場規模：地域別
- 北米の多発性骨髄腫市場規模
- ヨーロッパの多発性骨髄腫市場規模
- アジア太平洋の多発性骨髄腫市場規模
- 中南米/中東・アフリカの多発性骨髄腫市場規模
・競争状況
・企業情報

多発性骨髄腫市場の2021年の市場規模は196億6,674万ドルと評価され、2031年には535億2,176万ドルに達すると推定されています。2022年から2031年までの年平均成長率は10.5%となる見込みです。多発性骨髄腫は、形質細胞と呼ばれる白血球の一種にできるがんです。健康な形質細胞は、微生物を認識して増殖を抑制する抗体を合成することで、感染症との闘いに貢献しています。多発性骨髄腫では、がん化した形質細胞が骨髄に蓄積し、健康な血液細胞を押し出します。多発性骨髄腫の治療には、標的療法、免疫療法、化学療法、副腎皮質ステロイド、骨髄移植、放射線療法など、様々な治療法があります。

世界の多発性骨髄腫市場の成長を牽引しているのは、多発性骨髄腫治療薬を製造する市場プレイ ヤーの増加です。また、多発性骨髄腫治療薬の上市数や承認数の増加は、市場の成長を促進すると予想されます。例えば、2022年1月、製薬会社のBristol-Myers Squibb社は、B細胞成熟抗原（BCMA）指向性キメラ抗原受容体（CAR）T細胞免疫療法であるAbecma（イデカブタジェンビクリューセル）を、再発または難治性（R/R）の多発性骨髄腫の成人患者の治療薬として厚生労働省が承認したと発表しました。加えて、多発性骨髄腫の有病率の上昇が多発性骨髄腫治療薬の需要を押し上げ、市場の成長に拍車をかけています。例えば、国際がん研究機関によると、2020年には世界中で約1,76,404例の多発性骨髄腫が報告されています。

さらに、医療サービスに対する政府支出の増加は、病院や診療所による癌治療や癌治療薬の採用を促進し、それによって市場の成長を促進すると予想されます。例えば、国家統計局によると、2021年の英国の総医療費は300兆700億ドルで、2020年の支出に比べ名目ベースで7.4%増加したと報告されています。また、メディケア医療サービス政府センター（CMS）によると、2021年の国民医療費（NHE）は2.7％増の4.3兆ドル、1人当たり12,914ドルで、GDPの18.3％を占めると報告されています）。

一方、多発性骨髄腫治療薬、放射線療法、幹細胞移植の高額な費用や、治療薬に伴う副作用が多発性骨髄腫市場の成長を阻害しています。しかし、米国、カナダ、ドイツなどの先進国における医療サービスに対する需要の増加や、新興国における高い市場成長の可能性は、予測期間中に市場に大きな機会をもたらすと期待されています。

世界の多発性骨髄腫市場は、薬剤タイプ、疾患タイプ、エンドユーザー、地域に区分されます。
薬剤タイプ別では、市場は化学療法、プロテアーゼ阻害剤、モノクローナル抗体、その他に分けられます。
疾患タイプ別では、活動性多発性骨髄腫とくすぶり型多発性骨髄腫に二分されます。
エンドユーザー別では、病院、診療所、その他に分類されます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（中国、日本、インド、オーストラリア、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、サウジアラビア、南アフリカ、その他のLAMEA地域）で分析されています。

世界の多発性骨髄腫市場で事業を展開する主な主要企業は、Novartis AG、Bristol-Myers Squibb Company、Amgen Inc.、AbbVie Inc.、Johnson & Johnson、Teva Pharmaceutical Industries Ltd.、小野薬品工業株式会社、武田薬品工業株式会社、Roche Groupです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの多発性骨髄腫市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、多発性骨髄腫市場の有力な機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・多発性骨髄腫市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を、世界市場に対する収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現 在のポジションを明確に理解することができます。
・地域別、世界別の多発性骨髄腫市場動向、主要企業、市場セグメント、応用分野、市場成長戦略などの分析を収録しています。

〈主要市場セグメント〉
薬剤タイプ別
化学療法
プロテアーゼ阻害剤
モノクローナル抗体
その他

エンドユーザー別
病院
クリニック
その他

疾患タイプ別
活動性多発性骨髄腫
くすぶり型多発性骨髄腫

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Bristol-Myers Squibb Company
Amgen Inc.
Abbvie Inc
Johnson and Johnson
Baxter International Inc.
武田薬品工業株式会社
Teva Pharmaceutical Industries
Pfizer Inc.
Sanofi
Novartis AG

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of multiple myeloma
3.4.1.2. Increase in initiative taken by government for treatment of multiple myeloma
3.4.1.3. Rise in number of market players who manufactures multiple myeloma drugs

3.4.2. Restraints
3.4.2.1. High cost of multiple myeloma treatment
3.4.2.2. Side effects of multiple myeloma treatment

3.4.3. Opportunities
3.4.3.1. Increase in product launches and product approvals for multiple myeloma drugs

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: MULTIPLE MYELOMA MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Protease Inhibitors
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Monoclonal Antibody
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: MULTIPLE MYELOMA MARKET, BY DISEASE TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Active Multiple Myeloma
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Smoldering Multiple Myeloma
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: MULTIPLE MYELOMA MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Clinics
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: MULTIPLE MYELOMA MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Disease Type
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Type
7.2.5.1.3. Market size and forecast, by Disease Type
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Type
7.2.5.2.3. Market size and forecast, by Disease Type
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Type
7.2.5.3.3. Market size and forecast, by Disease Type
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Disease Type
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Type
7.3.5.1.3. Market size and forecast, by Disease Type
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Type
7.3.5.2.3. Market size and forecast, by Disease Type
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Type
7.3.5.3.3. Market size and forecast, by Disease Type
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Type
7.3.5.4.3. Market size and forecast, by Disease Type
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Type
7.3.5.5.3. Market size and forecast, by Disease Type
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Type
7.3.5.6.3. Market size and forecast, by Disease Type
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Disease Type
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Type
7.4.5.1.3. Market size and forecast, by Disease Type
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Type
7.4.5.2.3. Market size and forecast, by Disease Type
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Type
7.4.5.3.3. Market size and forecast, by Disease Type
7.4.5.3.4. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Type
7.4.5.4.3. Market size and forecast, by Disease Type
7.4.5.4.4. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Type
7.4.5.5.3. Market size and forecast, by Disease Type
7.4.5.5.4. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Type
7.4.5.6.3. Market size and forecast, by Disease Type
7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Disease Type
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Type
7.5.5.1.3. Market size and forecast, by Disease Type
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Type
7.5.5.2.3. Market size and forecast, by Disease Type
7.5.5.2.4. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Type
7.5.5.3.3. Market size and forecast, by Disease Type
7.5.5.3.4. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Type
7.5.5.4.3. Market size and forecast, by Disease Type
7.5.5.4.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Novartis AG
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Bristol-Myers Squibb Company
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Amgen Inc.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Abbvie Inc
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Sanofi
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Johnson and Johnson
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Baxter International Inc.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Takeda Pharmaceutical Company Ltd
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Teva Pharmaceutical Industries
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Pfizer Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 02. MULTIPLE MYELOMA MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 03. MULTIPLE MYELOMA MARKET FOR PROTEASE INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 04. MULTIPLE MYELOMA MARKET FOR MONOCLONAL ANTIBODY, BY REGION, 2021-2031 ($MILLION)
TABLE 05. MULTIPLE MYELOMA MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 06. GLOBAL MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 07. MULTIPLE MYELOMA MARKET FOR ACTIVE MULTIPLE MYELOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 08. MULTIPLE MYELOMA MARKET FOR SMOLDERING MULTIPLE MYELOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 09. GLOBAL MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 10. MULTIPLE MYELOMA MARKET FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. MULTIPLE MYELOMA MARKET FOR CLINICS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. MULTIPLE MYELOMA MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. MULTIPLE MYELOMA MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 14. NORTH AMERICA MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 15. NORTH AMERICA MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 16. NORTH AMERICA MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 17. NORTH AMERICA MULTIPLE MYELOMA MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. U.S. MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 19. U.S. MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 20. U.S. MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 21. CANADA MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 22. CANADA MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 23. CANADA MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 24. MEXICO MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 25. MEXICO MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 26. MEXICO MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 27. EUROPE MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 28. EUROPE MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 29. EUROPE MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 30. EUROPE MULTIPLE MYELOMA MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. GERMANY MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 32. GERMANY MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 33. GERMANY MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 34. FRANCE MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 35. FRANCE MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 36. FRANCE MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 37. UK MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 38. UK MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 39. UK MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 40. ITALY MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 41. ITALY MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 42. ITALY MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 43. SPAIN MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 44. SPAIN MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 45. SPAIN MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 46. REST OF EUROPE MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 47. REST OF EUROPE MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 48. REST OF EUROPE MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 49. ASIA-PACIFIC MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 50. ASIA-PACIFIC MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 51. ASIA-PACIFIC MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 52. ASIA-PACIFIC MULTIPLE MYELOMA MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 53. JAPAN MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 54. JAPAN MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 55. JAPAN MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 56. CHINA MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 57. CHINA MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 58. CHINA MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 59. INDIA MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 60. INDIA MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 61. INDIA MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 62. AUSTRALIA MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 63. AUSTRALIA MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 64. AUSTRALIA MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 65. SOUTH KOREA MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 66. SOUTH KOREA MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 67. SOUTH KOREA MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 71. LAMEA MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 72. LAMEA MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 73. LAMEA MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 74. LAMEA MULTIPLE MYELOMA MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 75. BRAZIL MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 76. BRAZIL MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 77. BRAZIL MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 78. SAUDI ARABIA MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 79. SAUDI ARABIA MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 80. SAUDI ARABIA MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 81. SOUTH AFRICA MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 82. SOUTH AFRICA MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 83. SOUTH AFRICA MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 84. REST OF LAMEA MULTIPLE MYELOMA MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 85. REST OF LAMEA MULTIPLE MYELOMA MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 86. REST OF LAMEA MULTIPLE MYELOMA MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 87. NOVARTIS AG: KEY EXECUTIVES
TABLE 88. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 89. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 90. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 91. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 92. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 93. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 94. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 95. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 96. AMGEN INC.: KEY EXECUTIVES
TABLE 97. AMGEN INC.: COMPANY SNAPSHOT
TABLE 98. AMGEN INC.: PRODUCT SEGMENTS
TABLE 99. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 100. AMGEN INC.: KEY STRATERGIES
TABLE 101. ABBVIE INC: KEY EXECUTIVES
TABLE 102. ABBVIE INC: COMPANY SNAPSHOT
TABLE 103. ABBVIE INC: PRODUCT SEGMENTS
TABLE 104. ABBVIE INC: PRODUCT PORTFOLIO
TABLE 105. ABBVIE INC: KEY STRATERGIES
TABLE 106. SANOFI: KEY EXECUTIVES
TABLE 107. SANOFI: COMPANY SNAPSHOT
TABLE 108. SANOFI: PRODUCT SEGMENTS
TABLE 109. SANOFI: PRODUCT PORTFOLIO
TABLE 110. SANOFI: KEY STRATERGIES
TABLE 111. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 112. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 113. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
TABLE 114. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 115. JOHNSON AND JOHNSON: KEY STRATERGIES
TABLE 116. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
TABLE 117. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
TABLE 118. BAXTER INTERNATIONAL INC.: PRODUCT SEGMENTS
TABLE 119. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
TABLE 120. TAKEDA PHARMACEUTICAL COMPANY LTD: KEY EXECUTIVES
TABLE 121. TAKEDA PHARMACEUTICAL COMPANY LTD: COMPANY SNAPSHOT
TABLE 122. TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCT SEGMENTS
TABLE 123. TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCT PORTFOLIO
TABLE 124. TAKEDA PHARMACEUTICAL COMPANY LTD: KEY STRATERGIES
TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES: KEY EXECUTIVES
TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT
TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES: PRODUCT SEGMENTS
TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO
TABLE 129. PFIZER INC.: KEY EXECUTIVES
TABLE 130. PFIZER INC.: COMPANY SNAPSHOT
TABLE 131. PFIZER INC.: PRODUCT SEGMENTS
TABLE 132. PFIZER INC.: PRODUCT PORTFOLIO

★調査レポート[多発性骨髄腫の世界市場2021-2031：機会分析・産業予測] (コード：ALD23JUN070)販売に関する免責事項を必ずご確認ください。
★調査レポート[多発性骨髄腫の世界市場2021-2031：機会分析・産業予測]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 神経変性治療薬の世界市場2021-2031：機会分析・産業予測
  • 結核治療薬の世界市場2021-2031：機会分析・産業予測
  • 乗り物酔い治療薬の世界市場2021-2031：機会分析・産業予測
  • アテローム切除術機器の世界市場2021-2031：機会分析・産業予測
  • 尿分析検査の世界市場2021-2031：機会分析・産業予測
  • 個別化医療の世界市場2021-2031：機会分析・産業予測
  • リハビリテーション装置の世界市場2021-2031：機会分析・産業予測
  • セントラルラボの世界市場2022-2031：機会分析・産業予測
  • 注射ペンの世界市場2021-2031：機会分析・産業予測
  • 肥満介入装置の世界市場2021-2031：機会分析・産業予測

    • ◆H&Iグローバルリサーチのお客様（例）◆